PDUFA VII: FDA, industry preview their reauthorization wish lists
At its first public meeting in the runup to the reauthorization of the Prescription Drug User Fee Act, the FDA, industry and other stakeholders on Thursday shed light on their goals for what will be the agency’s seventh PDUFA program.
The meeting, held fully virtually for the first time due to the COVID-19 pandemic, is the starting point for the negotiations with industry and discussions with stakeholders that will shape FDA’s new drug review program from FY2023-FY2027.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.